NMPA Innovative Medical Devices Rules: Propel China to be World Leader in Medical Innovation

NMPA published the “Implementation Rules for the Special Review of Innovative Medical Devices” on April 18, 2025. The document is based on the “Innovative Medical Devices Review Procedures” issued in 2018, detailing the path-to-market for novel medical technologies.

Significance of the Implementation Rules

The Implementation Rules consist of six chapters and 36 articles, covering General Provisions, Innovation Application and Formal Review, Expert Selection, Expert Review, Objection Handling, among others.

According to the detailed rules, the Center for Medical Device Evaluation (CMDE) has established the Office for Innovation Medical Device Review. The office is staffed by personnel dispatched from the NMPA’S Department of Medical Device Registration, the CMDE, the Chinese Society of Biomedical Engineering, and the Chinese Society for Biomaterials.

The document states that the review of innovation applications adopts an expert review system, with experts randomly and blindly selected through an expert management system. The Secretariat of the Innovation Review Office conducts a formal review of the innovation application materials, which include documents on product intellectual property rights and supporting evidence, a summary of the product’s research and development process and results, technical documentation, proof of the product’s innovativeness, and product risk analysis materials. After receiving the notice of the expert review meeting and the requirements for meeting materials, applicants may submit a presentation and video based on their application materials, and may also choose to attend the meeting online to answer questions from the expert panel.

For foreign manufacturers, the implications are clear: China is not only welcoming innovation but actively facilitating its growth. By streamlining the review process for cutting-edge devices with substantial clinical value and domestic originality, the country aims to foster an ecosystem that values both regulatory rigor and scientific advancement. These rules ensure greater transparency, shorter approval times, and more direct channels for communication between developers and regulatory authorities.

For the qualification of innovative device status, please click HERE

Step-by-Step Guidance: How the Special Review Process Works

The Implementation Rules lay out a structured and detailed process for applying for a special review designation under China’s innovative device pathway. Here’s a breakdown of how the system operates:

1. Eligibility Criteria
   Foreign manufacturers may apply for special review status if their products demonstrate significant clinical advantages, are based on core patented technologies, and are first-of-its-kind in China.
2. Application Submission
   The manufacturer, or its authorized Chinese agent, must submit an application that includes:
   • Completed Special Review Application Form.
   • Company qualification documents.
   • Intellectual property (IP) certificates, with emphasis on patents granted within the last five years.
   • A comprehensive overview of the R&D process, including lab research, animal and clinical trials.
   • Technical dossiers outlining mechanism of action, intended use, and performance benchmarks.
   • Risk assessment materials and sample product labeling.
   • Proof of compliance with Chinese medical device classification standards.
3. Formal Examination
   The Innovation Review Office (under CMDE) will conduct a formal examination to assess whether all documentation is complete and compliant with the requirements.
4. Expert Panel Review
   Eligible applications proceed to the expert panel stage. Experts are selected randomly through a blind selection process, ensuring objectivity and domain expertise. They evaluate whether the product qualifies for expedited review based on innovation, patent status, and clinical necessity.
5. Meeting and Presentation
   Applicants are invited to participate in an expert review meeting, either virtually or in person, where they present a detailed explanation of the product’s innovative aspects. Supplementary materials, such as presentations and explanatory videos, are submitted in advance.
6. Final Review and Public Notification
   After expert review, the Innovation Review Office finalizes the decision. If approved, the product is publicly listed on the CMDE website for a 10-day comment period before entering the special fast-track approval process.
7. Appeals and Communication
   If an application is rejected, manufacturers are entitled to a feedback meeting and may resubmit with additional evidence or modifications. Furthermore, any institution or individual can file objections during the public notification period, ensuring open and fair oversight.

Important Considerations for Foreign Manufacturers

While the new guidelines open doors for international players, they also underscore the importance of thorough preparation and localized strategy. Below are several key considerations:

1. Patent Localization
   Products must have relevant patents filed or granted in China, not just abroad. Patents licensed from other entities must come with comprehensive documentation, including licensing agreements and formal filings with the China National Intellectual Property Administration.
2. Chinese Language Requirements
   All materials submitted must be in Chinese or accompanied by certified translations. This includes technical files, clinical study data, and all patent documentation.
3. Regulatory Agent Representation
   Foreign companies must designate a qualified local agent responsible for regulatory affairs. This agent will act as the liaison between the applicant and Chinese authorities and must have experience navigating China’s National Medical Products Administration (NMPA) system.
4. Clinical Trial Expectations
   Clinical data submitted must be ethically sourced, preferably with Chinese patient data. If relying on overseas trials, justification for data extrapolation must be strong and supported by published studies or local expert opinions.
5. Disclosure and Transparency
   Applicants must disclose all parties involved in product development, including research institutions, subcontractors, and testing labs. Any conflicts of interest, such as relationships with expert reviewers or consultants, must be clearly stated.
6. Timing Strategy
   The special review application must be submitted before the initial registration process for the product begins in China. Therefore, early planning is essential to avoid delays or disqualification.
7. Reapplication Rules
   In cases of previous rejections, reapplying is possible only with substantial improvements or new evidence. Applicants must submit detailed reports highlighting changes and enhancements from earlier versions.